Perspective on Plasma Polymers for Applied Biomaterials Nanoengineering and the Recent Rise of Oxazolines
Macgregor M., Vasilev K.
Narrative Review, published in Materials (Basel) (2019) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Materials (Basel) (2019)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 30626075
- PMCID
- PMC6337614
- DOI
- 10.3390/ma12010191
- Citations
- 25
Abstract (original English)
Plasma polymers are unconventional organic thin films which only partially share the properties traditionally attributed to polymeric materials. For instance, they do not consist of repeating monomer units but rather present a highly crosslinked structure resembling the chemistry of the precursor used for deposition. Due to the complex nature of the deposition process, plasma polymers have historically been produced with little control over the chemistry of the plasma phase which is still poorly understood. Yet, plasma polymer research is thriving, in par with the commercialisation of innumerable products using this technology, in fields ranging from biomedical to green energy industries. Here, we briefly summarise the principles at the basis of plasma deposition and highlight recent progress made in understanding the unique chemistry and reactivity of these films. We then demonstrate how carefully designed plasma polymer films can serve the purpose of fundamental research and biomedical applications. We finish the review with a focus on a relatively new class of plasma polymers which are derived from oxazoline-based precursors. This type of coating has attracted significant attention recently due to its unique properties.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.